Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit).
Epistemonikos ID: d001b6cc41b78ed0a8e082043f9f1cf2222419a1
First added on: May 13, 2024